Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Jiang,Hong; Yu,Xin-Ming; Zhou,Xing-Ming; Wang,Xiao-Hong; Su,Dan

doi:10.3892/etm.2013.1007

Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Authors:
- Hong Jiang
- Xin-Ming Yu
- Xing-Ming Zhou
- Xiao-Hong Wang
- Dan Su
View Affiliations

Affiliations: Department of Thoracic Surgery, Key Laboratory of Thoracic Tumor Diagnosis (Esophagus, Lung) and Treatment Technology Research, Hangzhou, Zhejiang 310022, P.R. China, Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: March 14, 2013 https://doi.org/10.3892/etm.2013.1007
Pages: 1506-1510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the correlation between mRNA expression of β-tubulin-III and stathmin in patients with stage II non-small cell lung cancer (NSCLC) and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. A single‑gene quantitative test was performed to detect the mRNA expression of β-tubulin-III and stathmin in the tumor tissue of patients with stage II NSCLC. All the patients underwent NP treatment following surgery and were followed-up to record their disease‑free survival (DFS) and overall survival (OS). Statistical analyses were conducted to investigate the correlation between β-tubulin-III and stathmin mRNA expression and DFS and OS in the patients. β-tubulin-III mRNA expression was associated with OS in the 73 patients (P=0.003) and DFS was correlated with β-tubulin-III mRNA expression and lymphatic metastasis (P<0.01). Stathmin mRNA expression was not correlated with OS or DFS (P>0.05). OS and DFS were longer in the patients with low β-tubulin-III mRNA expression than in those with high β-tubulin-III mRNA expression (P<0.01); there was no significant change in OS and DFS between the patients with high and low mRNA expression of stathmin (P>0.05). The mRNA expression levels of β-tubulin-III in the tumor tissue of patients with stage II NSCLC may be considered as an index of prognosis and chemosensitivity, as well as a reference for personalized chemotherapeutic applications in patients.

View Figures

View References

1.	Volz A, Weiss E, Trowsdale J and Ziegler A: Presence of an expressed beta-tubulin gene (TUBB) in the HLA class I region may provide the genetic basis for HLA-linked microtubule dysfunction. Hum Genet. 93:42–6. 1994. View Article : Google Scholar : PubMed/NCBI
2.	Séve P and Dumontet C: Class III beta tubulin expression in non-small cell lung cancer. Rev Mal Respir. 27:383–386. 2010.(In French).
3.	Jeon TY, Han ME, Lee YW, et al: Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer. 102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Gan L, Guo K, Li Y, et al: Up-regulated expression of stathmin may be associated with hepatocarcinogenesis. Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
5.	Yuan SF, Chen WJ, Zhu LJ, et al: Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line. Asian Pac J Cancer Prev. 13:2967–2971. 2012. View Article : Google Scholar : PubMed/NCBI
6.	Eastham LL, Mills CN and Niles RM: PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells. Pharm Res. 25:1327–1333. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ER-CC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Bepler G, Kusmartseva I, Sharma S, et al: RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol. 24:4731–4737. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Papadaki C, Tsaroucha E, Kaklamanis L, et al: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer. 104:316–323. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Papadaki C, Sfakianaki M, Ioannidis G, et al: ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. J Thorac Oncol. 7:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Mariani M, Shahabi S, Sieber S, Scambia G and Ferlini C: Class III β-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med. 11:726–731. 2011.
13.	Koh Y, Jang B, Han SW, et al: Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol. 5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Séve P, Lai R, Reiman T, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small-cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res. 13:994–999. 2007.PubMed/NCBI
15.	Séve P, Isaac S, Trédan O, et al: Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486. 2005.
16.	Reiman T, Lai R, Veillard AS, et al: Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann Oncol. 23:86–93. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ and Purohit A: Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 102:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Hansch C and Verma RP: Understanding tubulin/microtubule-taxane interactions: a quantitative structure-activity relationship study. Mol Pharm. 5:151–161. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Singer S, Malz M, Herpel E, et al: Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res. 69:2234–2243. 2009. View Article : Google Scholar
20.	Pu X, Wang J, Xu L, et al: Relationship between expression of beta-tubulin-III plus stathmin in advanced non-small cell lung cancer and its sensitivity to venorelbine chemotherapy. Zhongguo Fei Ai Za Zhi. 12:49–53. 2009.(In Chinese).
21.	Singer S, Malz M, Herpel E, et al: Coordinated expression of stathmin family members by far upstream sequence element binding protein-1 increases motility in non-small cell lung cancer. J Cancer Res. 69:2234–2243. 2009. View Article : Google Scholar : PubMed/NCBI